Key result
OAC discontinuation post-AF ablation remains an option for low-risk patients arrhythmia-free at 12 months.
Why the study?
Questions increasingly arise regarding oral anticoagulation discontinuation in patients with AF who remain arrhythmia-free after ablation following recent trials reporting low stroke rates.
Is it safe to discontinue oral anticoagulation in patients with atrial fibrillation who remain arrhythmia-free after ablation?
Is it safe to discontinue oral anticoagulation in patients with atrial fibrillation who remain arrhythmia-free after ablation?
Before considering OAC discontinuation after AF ablation, patients should meet strict criteria including 12-month arrhythmia-free status, low thromboembolic risk, and access to intensified rhythm monitoring.
Maintain OAC post-AF ablation absent validated monitoring; leaves open optimal selection and long-term safety in broader cohorts.
Hospital pharmacists increasingly receive questions about oral anticoagulation (OAC) discontinuation in patients with atrial fibrillation (AF) who remain arrhythmia-free after ablation. Two recent trials, ALONE-AF and OCEAN, reported low annual stroke rates in selected post-ablation cohorts, suggesting limited added stroke protection from OAC in this group. Both studies have key limitations: selective low-risk patient populations, insufficient power for thromboembolic events, limited external validity to older AF patients, and methodological concerns including ALONE-AF's fragility index and OCEAN's comparator choice. Before OAC discontinuation is considered, multiple criteria should be met: first-time ablation with documented 12 month arrhythmia-free status, low thromboembolic risk, absence of prior cerebrovascular events and access to intensified rhythm monitoring, acknowledging that no validated monitoring strategy currently exists to guide anticoagulation decisions after ablation.
No takes yet. Share an insight, caveat, or question.
Linden et al. (2026) studied this question. OAC discontinuation post-AF ablation may be considered in low-risk, first-time ablation patients arrhythmia-free at 12 months, but lacks validated monitoring strategies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: